Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer/PPD Implitapide Development Follows Zetia Model As Statin Add-On

Executive Summary

PPD will adopt Merck/Schering-Plough's Zetia model in developing Bayer's implitapide as an add-on therapy in the lipid-lowering market, PPD subsidiary MRL International CEO Evan Stein, MD/PhD, said

You may also be interested in...



Schering Sales Force Recruitment Is 80% Complete; Morale Remains High

Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26

Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says

Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels

Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?

Bristol-Myers Squibb's Pravachol is gaining share in the retail market in the early days following the withdrawal of Bayer's Baycol, prescription tracking data from ArcLight indicate.

UsernamePublicRestriction

Register

PS043331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel